MedPage Today (10/5, Monaco) reported, “Among patients with schizophrenia, most preferred long-acting injectable antipsychotics when given a choice,” research indicated. “A post-hoc analysis of a randomized, controlled study found 77% of the 1,402 participants surveyed preferred long-acting injectable (LAI) antipsychotics over daily” oral medications, “according to a poster presented…at Psych Congress 2019.”
Related Links:
— MedPage Today (requires login and subscription)